TransLink member achieve an ERC starting grant.

Vered-Padler-Karavani1Dr Vered Padler-Karavani From Tel-Aviv University has been awarded with an important grant from the European Research Council for the project entitled “Selective glycoimmuno-targeting for cancer therapy, SweetAim”,

SweetAim’s objective is to design a novel personalized cancer therapeutic approach based on xeno-autoantibodies against the dietary sugar antigen

Dr  Padler-Karavani work is an innovative interdisciplinary approach crossing the boundaries of cancer research, glycosciences, immunology and nanotechnology, with cutting-edge technologies, to design, engineer, screen and fully investigate potent targeting of ‘SweetAim’ moieties.

The project will continue until late 2021 and have a budget of almost 1,5 million Euro which will allow Dr Padler-Karavani to become leader in Glycoimmunology